All In Biotech

Drug Trial Radar · NCT00803738

Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis

A Multi-center, Randomized, Investigator-blinded, Parallel-group Study, Designed to Evaluate the Safety and Clinical Equivalence of Terconazole Vaginal Suppositories, 80 mg (Test Product) and Terconazole Vaginal Suppositories, 80 mg (Reference Product) in the Treatment of Vulvovaginal Candidiasis Caused by Candida Species

Last checked: Nov 19, 2026Latest source record: Oct 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

572

Actual

Start

Dec 2002

Primary completion

Dec 2003

Study completion Dec 2003

Sponsor

Lead sponsor
Padagis LLCIndustry
Sponsor type
Industry
First posted
Dec 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of subjects with vulvovaginal candidiasis in order to establish bioequivalence.

Conditions

  • Vulvovaginal Candidiasis

Interventions

  • Terconazole Vaginal SuppositoryDrug

    Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days

  • Terazol Vaginal SuppositoryDrug

    Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects in Each Treatment Group With Therapeutic CureTime frame: Visit 3: Day 22-31

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.